ibrutinib,venetoclax
janssen,roche,Abbvie
['bet', 'glow']
updated glow data from dr. niemann - similar pfs for i+v treated patients regardless of mrd status at eot (better for mighv even though lower umrd) #ash22 
Associate clinical professor at UC Irvine focused on CLL/SLL and CHIP/CCUS/MDS. Animal and nature lover. Tweets are my own.